The contract development and manufacturing organization (CDMO) provides clinical and commercial manufacturing of therapeutic proteins.
Last week, the company announced the addition of a new building complex to house its global headquarters in Bothell, WA – allowing AGC Biologics to continue expansion in the US, according to the CDMO.
The complex spans more than 150,000 square feet and will house the company's process development labs and corporate administrative offices. Located near the existing AGC Biologics facility in Bothell, the new facility will include an R&D center dedicated to novel manufacturing technologies and also provides room for additional manufacturing capacity.
"The expansion of our Bothell site is another substantial milestone for AGC Biologics and a commitment to our operations in Washington State," said Gustavo Mahler, president and CEO of AGC Biologics, in a press release.
"These new state-of-the-art facilities will enable us to meaningfully advance and further integrate the development, manufacturing, and commercial functions within our dynamic global headquarters, as well as provide additional footprint for further manufacturing expansion."
AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics.
The company currently employs more than 850 employees across three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.